2024 SoLA

Targeting lipid and energy metabolism for cardiovascular diseases

Next generation NAD⁺ therapeutics via new modalities

Development of cardiovascular therapeutics through regulation of endothelial dysfunction

Precision nutrition through continuous glucose monitoring: decoding postprandial glycemic responses for cardiometabolic health

AI-based food drug interaction and clinical application in cardiometabolic diseases

Nutritional management as a GLP-1 adjuvant: bridging pharmacotherapy and dietary intervention for metabolic health

Decoding lipoprotein(a): genetics and measurement insights

Lipoprotein(a) epidemiology: Western and Korean data

Unveiling the clinical impact of lipoprotein(a)

Lipoprotein(a) as the next frontier in cardiovascular therapy

Genetic and mechanistic insights into triglyceride-rich lipoproteins and cardiometabolic disease

Omega-3 fatty acids: from triglyceride reduction to cardiovascular outcomes

APOC3 metabolism and therapeutic approaches

ANGPTL3/4/8 inhibition: translational insights and clinical development

CVD risk prediction in lipid guidelines

CVD risk prediction in diabetes guidelines

CVD risk prediction in hypertension guidelines

CVD risk prediction in the context of CKM health

이상지질혈증과 동맥경화치료의 시작과 유지의 어려운 이유

이상지질혈증과 동맥경화치료에 있어서 주요 가짜 정보의 유형 (매체에서 보이는 유형 정리)

가짜 정보에 의한 환자와 의료진의 피해 현황 (증례와 의료정보위원회 설문조사)

이상지질혈증과 동맥경화치료에 대한 복약순응도 향상 방안

CLVS 2025

VAS 2025

APSAVD 2025

AAS 2025

How should we apply the 2025 dyslipidemia guidelines in real-world Korean practice?

Early and intensive lipid-Lowering after acute coronary syndrome: timing, targets, and real-world challenges

Managing residual atherosclerotic risk: beyond LDL-C toward precision lipid therapy

HDL-C in the guidelines: where do we stand today?

HDL-C is cardioprotective — higher HDL-C reduces ASCVD risk

Extremely high HDL-C may be harmful — function matters more than quantity

TBD

TBD

TBD

AI 도구를 활용한 고품질 Peer Review 전략과 Reviewer Workflow 혁신

AI 시대의 에디터 역할과 출판 품질관리의 미래